Drug Information Update – FDA approves expanded use of drug to reduce the risk of melanoma returning after surgery

Drug Information Update – FDA approves expanded use of drug to reduce the risk of melanoma returning after surgery FDA Division of Drug Information: Know the Moment It Happens The Division of Drug Information (DDI) is CDER’s focal point for public inquiries. We serve the public by providing information on human drug products and drugContinue reading “Drug Information Update – FDA approves expanded use of drug to reduce the risk of melanoma returning after surgery”

Ipilimumab (Yervoy)

Ipilimumab (Yervoy) FDA approved ipilimumab (Yervoy Injection), for the additional indication of adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. October 28, 2015. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm470061.htm Source: FDA.GOV